

# Zhen-Bin Ding

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/772274/publications.pdf>

Version: 2024-02-01

42  
papers

2,541  
citations

279798

23  
h-index

265206

42  
g-index

42  
all docs

42  
docs citations

42  
times ranked

6609  
citing authors

#	ARTICLE	IF	CITATIONS
1	Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. <i>Molecular Oncology</i> , 2022, 16, 549-561.	4.6	21
2	KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. <i>Cancer Cell International</i> , 2022, 22, 128.	4.1	14
3	Laparoscopic hepatectomy enhances recovery for small hepatocellular carcinoma with liver cirrhosis by postoperative inflammatory response attenuation: a propensity score matching analysis with a conventional open approach. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 910-920.	2.4	13
4	Laparoscopic vs. Open Repeat Hepatectomy for Recurrent Liver Tumors: A Propensity Score-Matched Study and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 646737.	2.8	9
5	Abstract 486: A phase Ib/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC). <i>Cancer Research</i> , 2021, 81, 486-486.	0.9	7
6	Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. <i>Gut</i> , 2021, 70, 951-961.	12.1	93
7	Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. <i>BMC Cancer</i> , 2020, 20, 642.	2.6	9
8	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. <i>British Journal of Cancer</i> , 2020, 123, 92-100.	6.4	10
9	Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. <i>Annals of Translational Medicine</i> , 2020, 8, 487-487.	1.7	25
10	CCL15 Recruits Suppressive Monocytes to Facilitate Immune Escape and Disease Progression in Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 143-159.	7.3	105
11	Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1369-1378.	4.2	12
12	Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. <i>Journal of Cancer</i> , 2019, 10, 5575-5584.	2.5	28
13	Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. <i>BMC Medicine</i> , 2019, 17, 106.	5.5	31
14	Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2019, 19, 71.	4.1	92
15	Laparoscopic Versus Open Left Lateral Segmentectomy for Large Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2019, 29, 513-519.	0.8	6
16	Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. <i>Aging</i> , 2019, 11, 11111-11123.	3.1	6
17	Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , 2018, 69, 89-98.	3.7	63
18	MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma. <i>Cancer Letters</i> , 2018, 412, 108-117.	7.2	79

#	ARTICLE	IF	CITATIONS
19	SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 243-250.	6.1	16
20	Radiomics score: a potential prognostic imaging feature for postoperative survival of solitary HCC patients. <i>BMC Cancer</i> , 2018, 18, 1148.	2.6	113
21	Clinical significance of PD-1/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma. <i>Theranostics</i> , 2018, 8, 5690-5702.	10.0	45
22	A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. <i>Journal of Cancer</i> , 2018, 9, 1025-1032.	2.5	14
23	Autophagy activation contributes to glutathione transferase Mu mediated chemoresistance in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 16, 346-352.	1.8	12
24	Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. <i>Journal of Cancer</i> , 2018, 9, 1106-1112.	2.5	16
25	Telomere length variation in tumor cells and cancer-associated fibroblasts: potential biomarker for hepatocellular carcinoma. <i>Journal of Pathology</i> , 2017, 243, 407-417.	4.5	22
26	FOXP3 Is a HCC suppressor gene and Acts through regulating the TGF- $\beta$ /Smad2/3 signaling pathway. <i>BMC Cancer</i> , 2017, 17, 648.	2.6	32
27	Association of hepatitis status with surgical outcomes in patients with dual hepatitis B and C related hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , 2017, 12, 28.	2.6	2
28	Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents. <i>Gastroenterology</i> , 2017, 152, 232-242.e4.	1.3	107
29	Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. <i>BMC Cancer</i> , 2017, 17, 762.	2.6	12
30	CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. <i>Oncotarget</i> , 2017, 8, 5135-5148.	1.8	35
31	Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity. <i>Oncotarget</i> , 2016, 7, 2867-2877.	1.8	38
32	Lamp2a is required for tumor growth and promotes tumor recurrence of hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2016, 49, 2367-2376.	3.3	39
33	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 169-178.	1.5	32
34	Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epidermal growth factor receptor induced epithelial-mesenchymal transition. <i>Hepatology</i> , 2015, 62, 1201-1214.	7.3	49
35	Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. <i>International Journal of Oncology</i> , 2015, 46, 587-596.	3.3	177
36	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 846-861.	1.8	84

#	ARTICLE	IF	CITATIONS
37	Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients. <i>Gastroenterology</i> , 2014, 146, 1397-1407.	1.3	111
38	Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. <i>Autophagy</i> , 2013, 9, 2056-2068.	9.1	222
39	Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. <i>Autophagy</i> , 2011, 7, 1159-1172.	9.1	287
40	Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation. <i>Clinical Cancer Research</i> , 2011, 17, 6229-6238.	7.0	162
41	Liver-intestine cadherin predicts microvascular invasion and poor prognosis of hepatitis B virus-positive hepatocellular carcinoma. <i>Cancer</i> , 2009, 115, 4753-4765.	4.1	46
42	Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 9167-9175.	0.9	245